Morgan Stanley Upgrades Ionis Pharmaceuticals on Strong Tryngolza Launch Morgan Stanley has upgraded Ionis Pharmaceuticals stock, signaling increased confidence in the company’s future prospects following the successful launch of its...
UK Court Allows Appeal Against Palestine Action Terrorist Designation A London High Court judge has ruled that Palestine Action, a pro-Palestinian protest group, has the right to appeal the UK...
Oppenheimer Lowers UnitedHealth Price Target, Signaling Reset Expectations Oppenheimer analysts have lowered their price target for UnitedHealth Group (UNH) to $325, indicating a recalibration of expectations for the healthcare giant....
Boeing Stock Soars After Bernstein Raises Price Target to $287 on Strong Q2 Results Boeing’s stock price received a significant boost after Bernstein Research raised its price target to $287,...
Bernstein Boosts Alnylam’s Price Target on Promising Amvuttra Outlook Alnylam Pharmaceuticals received a vote of confidence from Bernstein, with the investment firm raising its price target on the biotech company’s...
Bernstein Boosts Sarepta Therapeutics Price Target to $18 Following Elevidys Approval Bernstein has raised its price target for Sarepta Therapeutics stock to $18 from a previous level, following the FDA’s...
Boeing Stock Price Target Rises as Susquehanna Boosts Outlook Susquehanna analysts have raised their price target for Boeing stock to $270 from $265, signaling increased confidence in the aerospace giant’s...
Susquehanna Boosts AMD Price Target to $210 Amid China AI Export License Review Susquehanna has raised its price target for AMD to $210, citing the ongoing review of China’s AI...
Bernstein Boosts Hubbell’s Price Target to $511 on Positive Outlook Bernstein, a leading Wall Street research firm, has raised its price target for Hubbell Incorporated (HUBB) stock to $511, signaling...
Bernstein Maintains Neutral Stance on Titan America, Stock at $15 Bernstein analysts have reaffirmed their “Market Perform” rating for Titan America, maintaining their $15 price target. This suggests the investment...
